Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 5 | Biological Research

Fig. 5

From: Galectins in epithelial-mesenchymal transition: roles and mechanisms contributing to tissue repair, fibrosis and cancer metastasis

Fig. 5

Gal-1 pathways promoting EMT in cancer. (a) Gal-1 promotes EMT in gastric cancer cells through a TGFR-β/Smad pathway and can be blocked with the Gal-1 inhibitor ITD1. (b) Gal-1 secreted from gastric cancer cells or CAFs induces EMT through a mechanism involving β1-integrin and Gli-1. (c) Overexpression of Gal-1 in gastric cancer cells increases the levels of S1PR1 at the cell surface, which is required for Gal-1-induced EMT through an unknown pathway. (d) Overexpression of Gal-1 in ovarian cancer cells activates MAPK JNK/p38 signaling through an unknown mechanism promoting EMT. (e) Activation of TLR-4 induces Gal-1 via PI3K/AKT or ERK-AKT pathways leading to EMT. (f) Gal-1 overexpression in HCC cells induces EMT through a Integrin/FAK/PI3K/AKT pathway. (g-j) Examples of extracellular Gal-1 contribution to EMT, involving Ras/Rac1/MEKK4/JNK/AP (g) and FAK/PI3K/AKT/mTOR (h) in urothelial cancer cells, activation of NFkB signaling in pancreatic cancer cells (i) and activation of β -catenin pathway in colorectal cancer (j)

Back to article page

Biological Research

ISSN: 0717-6287

Contact us